Zobrazeno 1 - 10
of 38
pro vyhledávání: '"wa_115"'
Autor:
Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD, Com-COV2 Study Group
Publikováno v:
Lancet (London, England)
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5
Background Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72507942631237263460b52b50669b5
https://doi.org/10.1016/s0140-6736(21)02718-5
https://doi.org/10.1016/s0140-6736(21)02718-5
Autor:
Robert H Shaw, Xinxue Liu, Arabella S V Stuart, Melanie Greenland, Parvinder K Aley, Nick J Andrews, J Claire Cameron, Sue Charlton, Elizabeth A Clutterbuck, Andrea M Collins, Wanwisa Dejnirattisai, Tanya Dinesh, Saul N Faust, Daniela M Ferreira, Adam Finn, Christopher A Green, Bassam Hallis, Paul T Heath, Helen Hill, Teresa Lambe, Rajeka Lazarus, Vincenzo Libri, Fei Long, Yama F Mujadidi, Emma L Plested, Ella R Morey, Samuel Provstgaard-Morys, Maheshi N Ramasamy, Mary Ramsay, Robert C Read, Hannah Robinson, Gavin R Screaton, Nisha Singh, David P J Turner, Paul J Turner, Iason Vichos, Laura L Walker, Rachel White, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Alasdair P.S. Munro, Jazz Bartholomew, Laura Presland, Sarah Horswill, Sarah Warren, Sophie Varkonyi-Clifford, Stephen Saich, Kirsty Adams, Marivic Ricamara, Nicola Turner, Nicole Y. Yee Ting, Sarah Whittley, Tommy Rampling, Amisha Desai, Claire H. Brown, Ehsaan Qureshi, Karishma Gokani, Kush Naker, Johanna K. Kellett Wright, Rachel L. Williams, Tawassal Riaz, Florentina D. Penciu, Amy Carson, Claudio Di Maso, Gracie Mead, Elizabeth G. Howe, Mujtaba Ghulam Farooq, Rabiullah Noristani, Xin L. Yao, Neil J. Oldfield, Daniel Hammersley, Sue Belton, Simon Royal, Alberto San Francisco Ramos, Cecilia Hultin, Eva P. Galiza, Rebecca Crook, Marcin Bula, Fred Fyles, Hassan Burhan, Flora Maelin, Elen Hughes, Emmanuel Okenyi
Publikováno v:
Shaw, R H, Liu, X, Stuart, A S V, Greenland, M, Aley, P K, Andrews, N J, Finn, A & Lazarus, R & et, A 2022, ' Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules : exploratory analyses of Com-COV, a randomised control trial ', Lancet Respiratory Medicine, vol. 10, no. 11, pp. 1049-1060 . https://doi.org/10.1016/S2213-2600(22)00163-1
Background Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses from the Com-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ed4ea510bf1be44fbc2afbfb9cf0590
https://eprints.soton.ac.uk/456454/
https://eprints.soton.ac.uk/456454/
Autor:
Todd D Swarthout, Marc Y R Henrion, Deus Thindwa, James E Meiring, Maurice Mbewe, Akuzike Kalizang’Oma, Comfort Brown, Jacquline Msefula, Brewster Moyo, Andrew A Mataya, Susanne Barnaba, Emma Pearce, Melita Gordon, David Goldblatt, Neil French, Robert S Heyderman
BACKGROUND: Pneumococcal conjugate vaccines (PCVs) induce serotype-specific IgG antibodies, effectively reducing vaccine-serotype carriage and invasive pneumococcal disease (IPD). IgG production wanes approximately 1 month after vaccination in absenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc54bb8b83f6bd3bcbd4c7909567cdba
https://archive.lstmed.ac.uk/21122/1/Lancet_Inf_Dis_1-s2.0-S1473309922004388-main.pdf
https://archive.lstmed.ac.uk/21122/1/Lancet_Inf_Dis_1-s2.0-S1473309922004388-main.pdf
Autor:
Marianne Koenraads, Todd D. Swarthout, Naor Bar-Zeev, Comfort Brown, Jacquline Msefula, Brigitte Denis, Queen Dube, Stephen B. Gordon, Robert S. Heyderman, Melissa J. Gladstone, Neil French
Publikováno v:
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Background: \ud \ud Invasive pneumococcal disease (IPD) in young infants is uncommon but associated with high morbidity and mortality. Accurate data on the burden of IPD in young infants in low-income countries are lacking. We examined the burden of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462618bf08fc41b1e88a6698ecde921e
https://pubmed.ncbi.nlm.nih.gov/35703302
https://pubmed.ncbi.nlm.nih.gov/35703302
Autor:
Bernard Appiah, Lucy Asamoah-Akuoko, Christopher France, Antonio Rene, Nathan Amanquah, Imelda Bates
Publikováno v:
Research in Social & Administrative Pharmacy
As several low- and middle-income countries roll out their COVID-19 vaccination programmes, COVID-19 vaccines hesitancy could threaten the success of such programmes. But pharmacists can play a leading role in addressing COVID-19 vaccine hesitancy by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::277688a4cc5017a5c6aeca6840620d57
Autor:
Praet, Nicolas, Asante, Kwaku Poku, Bozonnat, Marie‑Cecile, Akité, Elaine Jacqueline, Ansah, Patrick Odum, Baril, Laurence, Boahen, Owusu, Mendoza, Yolanda Guerra, Haine, Valerie, Kariuki, Simon, Lamy, Mathieu, Maleta, Kenneth, Mungwira, Randy, Ndeketa, Latif, Oduro, Abraham, Ogutu, Bernhards, Olewe, Fredrick, Oneko, Martina, Orsini, Mattéa, Roman, Francois, Bahmanyar, Edith Roset, Rosillon, Dominique, Schuerman, Lode, Sing’oei, Valentine, Terlouw, Anja, Wéry, Stéphanie, Otieno, Walter, Pirçon, Jean‑Yves
Publikováno v:
Malaria Journal. 21
Background Following a 30-year development process, RTS,S/AS01E (GSK, Belgium) is the first malaria vaccine to reach Phase IV assessments. The World Health Organization-commissioned Malaria Vaccine Implementation Programme (MVIP) is coordinating the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::979d919619c7830b74d76daa7a84e983
https://doi.org/10.1186/s12936-022-04144-3
https://doi.org/10.1186/s12936-022-04144-3
Autor:
Clare L. Cutland, Hugo Devlieger, Matthews Mathai, Barbee I. Whitaker, Christine Guillard Maure, Anke L. Stuurman, Neeraj Kumar Kashyap, Hui-Lee Wong, Varalakshmi Elango, Shubhashri Jahagirdar, Narendra K. Arora, Who Gvs Mcc Sites, Jorne Biccler, Steven A. Anderson, Punam Mangtani, Margarita Riera-Montes, Ramesh Poluru, Apoorva Sharan
Publikováno v:
Vaccine: X
Vaccine: X, Vol 9, Iss, Pp 100123-(2021)
Vaccine: X, Vol 9, Iss, Pp 100123-(2021)
Highlights • Applicability of GAIA definitions were assessed using medical records in LMICs. • LBW, preterm birth and neonatal death definitions were applicable in the field. • SGA, stillbirth, neonatal infection, congenital microcephaly defini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a3821d08453014a82373f82b2e9a8ed
https://archive.lstmed.ac.uk/19533/1/1-s2.0-S2590136221000401-main.pdf
https://archive.lstmed.ac.uk/19533/1/1-s2.0-S2590136221000401-main.pdf
Autor:
Dianne J. Terlouw, Sophie Biernaux, Donnie Mategula, Naor Bar-Zeev, Latif Ndeketa, Christophe Sauboin
Publikováno v:
Wellcome Open Research
Background: The RTS,S/AS01E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part of a large-scale pilot implementation programme. Even if impactful, its incorporation into immunisation programmes will depend on demonstrating cost-effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b137664a47f234a7e41b45be00cec17e
https://archive.lstmed.ac.uk/19244/1/wellcomeopenres-5-18918.pdf
https://archive.lstmed.ac.uk/19244/1/wellcomeopenres-5-18918.pdf
Autor:
Marjory Banda, Charles Mwansambo, Todd D. Swarthout, Uri Obolski, Andrea Gori, José Lourenço, Neil French, Thandie S. Mwalukomo, Arox W. Kamng’ona, Robert S. Heyderman, Naor Bar-Zeev, Sunetra Gupta, Andrew A. Mataya, Dean Everett
Publikováno v:
BMC Medicine, Vol 17, Iss 1, Pp 1-11 (2019)
Lourenço, J, Obolski, U, Swarthout, T D, Gori, A, Bar-Zeev, N, Everett, D, Kamng'ona, A W, Mwalukomo, T S, Mataya, A A, Mwansambo, C, Banda, M, Gupta, S, French, N & Heyderman, R S 2019, ' Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi : a modelling study ', BMC Medicine, vol. 17, no. 1, pp. 219 . https://doi.org/10.1186/s12916-019-1450-2
BMC Medicine
Lourenço, J, Obolski, U, Swarthout, T D, Gori, A, Bar-Zeev, N, Everett, D, Kamng'ona, A W, Mwalukomo, T S, Mataya, A A, Mwansambo, C, Banda, M, Gupta, S, French, N & Heyderman, R S 2019, ' Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi : a modelling study ', BMC Medicine, vol. 17, no. 1, pp. 219 . https://doi.org/10.1186/s12916-019-1450-2
BMC Medicine
Background In November 2011, Malawi introduced the 13-valent pneumococcal conjugate vaccine (PCV13) into the routine infant schedule. Four to 7 years after introduction (2015–2018), rolling prospective nasopharyngeal carriage surveys were performed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7871a9a485cf2b0e93f90c2b69867c7c
https://doaj.org/article/9877bc64ff514818960a5a41228f552e
https://doaj.org/article/9877bc64ff514818960a5a41228f552e
Autor:
Robert S. Heyderman, Dean Everett, Naor Bar-Zeev, Anne von Gottberg, Maaike Alaerts, Todd D. Swarthout, Jennifer R. Verani, Carina King, Neil French, Charles Mwansambo, Jacquline Msefula, Jane Mallewa, Stephen B. Gordon, Comfort Brown, Sithembile Bilima, Nigel A. Cunliffe, Cynthia G. Whitney
Publikováno v:
The Lancet Global Health
The Lancet Global Health, Vol 9, Iss 7, Pp e989-e998 (2021)
The Lancet. Global Health
The Lancet Global Health, Vol 9, Iss 7, Pp e989-e998 (2021)
The Lancet. Global Health
BACKGROUND\ud The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine and non-vaccine serotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaec5b311d40e8181ed018c045e0637e
https://hdl.handle.net/10067/1796830151162165141
https://hdl.handle.net/10067/1796830151162165141